Mary Kerby
Nurse Practitioner · Bella Vista, ARNPI 1811286750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 373 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$737
- Amgen$677
- Pfizer$607
- GSK$514
- Astellas Pharma US Inc$417
- Johnson & Johnson$360
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,740100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $737 |
| Amgen | 41 | $677 |
| Pfizer | 42 | $607 |
| GSK | 39 | $514 |
| Astellas Pharma US Inc | 24 | $417 |
| Johnson & Johnson | 23 | $360 |
| Novo Nordisk | 19 | $314 |
| AstraZeneca | 16 | $292 |
| Lilly USA, LLC | 18 | $248 |
| Bayer | 12 | $211 |
| Abbott | 9 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| Phathom Pharmaceuticals, Inc. | 7 | $107 |
| Kowa Pharmaceuticals America, Inc. | 8 | $103 |
| Boehringer Ingelheim | 6 | $90 |
| Mylan Specialty L.p. | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 5 | $72 |
| Merck | 5 | $72 |
| Exact Sciences | 4 | $64 |
| Dexcom, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $54 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Eisai Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| Biogen | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$5,740 in reported general payments places this provider in the 90th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $83,976 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $50,894 |
| JardianceEmpagliflozin | 33 | $34,876 |
| EliquisApixaban | 27 | $28,290 |
| ProliaDenosumab | 14 | $24,262 |
| XareltoRivaroxaban | 18 | $22,918 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $18,994 |
| MyrbetriqMirabegron | 22 | $12,352 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,979 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $8,090 |
| LinzessLinaclotide | 14 | $7,817 |
| Gabapentin | 178 | $3,999 |
| Levothyroxine Sodium | 425 | $3,291 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $3,253 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $3,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $314 | $83,97674 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $514 | $79,86891 claims |
| Boehringer IngelheimJardiance | $90 | $34,87633 claims |
| PfizerEliquis | $607 | $28,29027 claims |
| AmgenProlia | $677 | $24,26214 claims |
| Johnson & JohnsonXarelto | $360 | $22,91818 claims |
| Astellas Pharma US IncMyrbetriq | $417 | $12,35222 claims |
| AbbVieLinzess, Synthroid | $737 | $10,94245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Bella Vista
- Renee WilliamsBella Vista$8K
- Merideth HanksRogers$157K
- Angela JonesJonesboro$90K
- Tiffany McConathyHot Springs$54K
- Brenna FitzgeraldNorth Little Rock$46K
- Iris KennedyLittle Rock$22K
- Virginia LaliberteHot Springs$21K
- Julia PonderLittle Rock$21K
- Rhonda HillJonesboro$20K
- Dakota YoungFort Smith$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.